Canadian Respiratory Journal

Canadian Respiratory Journal / 2015 / Article

Clinico-Pathologic Conferences | Open Access

Volume 22 |Article ID 265734 | https://doi.org/10.1155/2015/265734

Samuel Yung, Duhyun Han, Jason K Lee, "Cutaneous Sarcoidosis in a Patient with Severe Asthma treated with Omalizumab", Canadian Respiratory Journal, vol. 22, Article ID 265734, 2 pages, 2015. https://doi.org/10.1155/2015/265734

Cutaneous Sarcoidosis in a Patient with Severe Asthma treated with Omalizumab

Abstract

Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been used as an effective treatment for severe asthma associated with atopy over the past decade. Sarcoidosis is an idiopathic granulomatous disorder in which first-line treatment is usually glucocorticoids. To the authors’ knowledge, the present report describes the first case of an association between omalizumab therapy and revelation of cutaneous sarcoidosis with the withdrawal of systemic glucocorticoids. A 56-year-old woman with severe allergic asthma dependent on oral prednisone initiated omalizumab treatment. As her symptoms of asthma improved over the course of a year, her prednisone was gradually tapered. After being off glucocorticoids, she developed skin nodules that had biopsy characteristics of sarcoidosis. The present case illustrates the need to monitor closely for potential unmasking of glucocorticoid-responsive conditions when transitioning from systemic glucocorticoids to omalizumab therapy.

Copyright © 2015 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views301
Downloads332
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.